Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure

 
• By Joseph Haas
3d rendering Human Heart
Vericiguat showed ability to reduce hospitalizations in high-risk heart failure patients, but not a mortality benefit

More from Clinical Trials

More from R&D